Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

• Status: Recruiting
• Trial end date: 2023-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: iCell Gene Therapeutics
• Collaborators: iCAR Bio; iCAR Bio Therapeutics Ltd.; Peking University Shenzhen Hospital

Criteria

Inclusion Criteria:

1. Signed written informed consent; Patients volunteer to participate in the research

2. Diagnosis is mainly based on the World Health Organization (WHO) 2008

3. Patients have exhausted standard therapeutic options

4. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks

5. Female must be not pregnant during the study

Exclusion Criteria:

1. Patients declining to consent for treatment

2. Prior solid organ transplantation

3. Potentially curative therapy including chemotherapy or hematopoietic cell transplant

4. Any drug used for GVHD must be stopped >1 week